Product
Patsnap Eureka
For R&D, Patsnap Eureka makes reading and utilizing patents & technical documents easy.
Patsnap Eureka AIR
Designed for self-driven R&D workflows. Generate viable solutions, solve complex R&D challenges, empower your innovation with AI.
Patsnap Eureka Materials
Designed for material experts only. Revolutionize your material R&D, from search, analyze, to developing new materials.
Feature
TechResearch
Generate reliable direction feasibility study reports for your R&D in just a few steps.
TechSeek
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
TechMind
As an expert in R&D Theories, TechMind can generates customized viable solutions instantly.
TechRisk
Analyze your overall solution with one click, know your potential R&D risks in advance.
TechMonitor
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
54 results about "Dystonia" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
Unintentional sustained muscle contractions leading to abnormal postures.
Movement disorder therapy system and methods of tuning remotely, intelligently and/or automatically
ActiveUS20140074180A1Maximize battery lifeImprove the quality of lifeHead electrodesMechanical/radiation/invasive therapiesHuntingtons choreaEssential tremor
The present invention relates to methods for remotely and intelligently tuning movement disorder of therapy systems. The present invention still further provides methods of quantifying movement disorders for the treatment of patients who exhibit symptoms of such movement disorders including, but not limited to, Parkinson's disease and Parkinsonism, Dystonia, Chorea, and Huntington's disease, Ataxia, Tremor and Essential Tremor, Tourette syndrome, stroke, and the like. The present invention yet further relates to methods of remotely and intelligently or automatically tuning a therapy device using objective quantified movement disorder symptom data to determine the therapy setting or parameters to be transmitted and provided to the subject via his or her therapy device. The present invention also provides treatment and tuning intelligently, automatically and remotely, allowing for home monitoring of subjects.
Owner:GREAT LAKES NEUROTECH
Movement disorder therapy system, devices and methods, and intelligent methods of tuning
ActiveUS20140074179A1Maximize battery lifeImprove the quality of lifeMedical simulationHead electrodesDiagnostic Radiology ModalityHuntingtons chorea
The present invention relates to methods for tuning treatment parameters in movement disorder therapy systems. The present invention further relates to a system for screening patients to determine viability as candidates for certain therapy modalities, such as deep brain stimulation (DBS). The present invention still further provides methods of quantifying movement disorders for the treatment of patients who exhibit symptoms of such movement disorders including, but not limited to, Parkinson's disease and Parkinsonism, Dystonia, Chorea, and Huntington's disease, Ataxia, Tremor and Essential Tremor, Tourette syndrome, stroke, and the like. The present invention yet further relates to methods of tuning a therapy device using objective quantified movement disorder symptom data acquired by a movement disorder diagnostic device to determine the therapy setting or parameters to be provided to the subject via his or her therapy device. The present invention also provides treatment and tuning remotely, allowing for home monitoring of subjects.
Owner:GREAT LAKES NEUROTECH
Movement disorder therapy system, devices and methods, and intelligent methods of tuning
ActiveUS9211417B2Expand accessShorten the timeMedical simulationHead electrodesHuntingtons choreaMovement disorders
The present invention relates to methods for tuning treatment parameters in movement disorder therapy systems. The present invention further relates to a system for screening patients to determine viability as candidates for certain therapy modalities, such as deep brain stimulation (DBS). The present invention still further provides methods of quantifying movement disorders for the treatment of patients who exhibit symptoms of such movement disorders including, but not limited to, Parkinson's disease and Parkinsonism, Dystonia, Chorea, and Huntington's disease, Ataxia, Tremor and Essential Tremor, Tourette syndrome, stroke, and the like. The present invention yet further relates to methods of tuning a therapy device using objective quantified movement disorder symptom data acquired by a movement disorder diagnostic device to determine the therapy setting or parameters to be provided to the subject via his or her therapy device. The present invention also provides treatment and tuning remotely, allowing for home monitoring of subjects.
Owner:GREAT LAKES NEUROTECHNOLOGIES INC
Derivate von dihydroxyphenylalanin
The invention relates to dihydroxyphenylalanine derivatives, the production thereof, and pharmaceutical compositions containing said dihydroxyphenylalanine derivatives. The invention further relates to the use of said dihydroxyphenylalanine derivatives and pharmaceutical compositions for the treatment and prevention of movement disorders, neurodegenerative diseases, Alzheimer, Parkinson's disease, hemiatrophy hemiparkinsonism, Parkinson's syndrome, Lewy bodies disease, frontotemporal dementia, Lytico-Bodig disease (Parkinsonism-dementia-amyotrophic lateral sclerosis, striatonigral degeneration, Shy-Drager syndrome, sporadic olivopontocerebellar degeneration, progressive pallidal atrophy, progressive supranuclear palsy, Hallervorden-Spatz disease, Huntington's disease, X chromosome-linked dystonia (Morbus Lubag), mitochondrial cytopathy with striatal necrosis, neuroacanthocytosis, restless leg syndrome, Wilson's disease.
Owner:ELLNEUROXX LTD
Method for treatment of movement disorders
The invention is directed to methods of treating movement disorders by administering an effective amount of the compound of formula (I) to patients in need thereof. More particularly, the invention is directed to a method for treating myoclonus including administering to a patient a compound of formula (I), wherein the myoclonus is not alcohol responsive essential myoclonus with dystonia. In some embodiments, the myoclonus is posthypoxic myoclonus. The invention is also directed to a method for treating dystonia, essential tremor cerebellar tremor, a tic, or chorea, including administering to a patient a compound of formula (I).
Owner:THE TRUSTEES OF COLUMBIA UNIV IN THE CITY OF NEW YORK
Movement disorder therapy system and methods of tuning remotely, intelligently and/or automatically
ActiveUS9238142B2Expand accessShorten the timeMechanical/radiation/invasive therapiesHead electrodesHuntingtons choreaEssential tremor
Owner:GREAT LAKES NEUROTECHNOLOGIES INC
Movement disorder therapy system and methods of tuning remotely, intelligently and/or automatically
ActiveUS9522278B1Expand accessShorten the timeHead electrodesMechanical/radiation/invasive therapiesHuntingtons choreaEssential tremor
The present invention relates to methods for remotely and intelligently tuning movement disorder of therapy systems. The present invention still further provides methods of quantifying movement disorders for the treatment of patients who exhibit symptoms of such movement disorders including, but not limited to, Parkinson's disease and Parkinsonism, Dystonia, Chorea, and Huntington's disease, Ataxia, Tremor and Essential Tremor, Tourette syndrome, stroke, and the like. The present invention yet further relates to methods of remotely and intelligently or automatically tuning a therapy device using objective quantified movement disorder symptom data to determine the therapy setting or parameters to be transmitted and provided to the subject via his or her therapy device. The present invention also provides treatment and tuning intelligently, automatically and remotely, allowing for home monitoring of subjects.
Owner:GREAT LAKES NEUROTECHNOLOGIES INC
Remedy for hypermyotonia
InactiveUS20050163809A1Short timeSolve the real problemBacterial antigen ingredientsSenses disorderHypermyotoniaMedicine
A remedy for muscle hyperactivity, comprising a purified botulinum neurotoxin as an active ingredient.
Owner:JURIDICAL FOUND THE CHEMO SERO THERAPEUTIC RES INST
Adenosine a2a receptor antagonists for the treatment of extra-pyramidal syndrome and other movement disorders
Owner:SCHERING CORP
Device for Complex Interval Normobaric Hypoxic Hyperoxic Training of a Human
InactiveUS20090183738A1Improve training effectShorten the lengthSemi-permeable membranesMembranesSide effectOxygen
This invention is directed to medical equipment and can be used for elevation of resistance of a human body against various pathologies including bronchial asthma, hyperplastic anemia and iron deficiency anemia, neurocirculatory dystonia, hypertension, obesity. This instrument can also be useful for treatment and prevention of respiratory and metabolic dysfunctions, for enhancement of non-specific compensatory capabilities of a human body and its aerobic output, as well as for improving physical fitness and regenerative ability of athletes, and reducing negative side effects of ionizing radiation.
Owner:VNIIMI GROUP OF
Adenosine A2a receptor antagonists for the treatment of extra-pyramidal syndrome and other movement disorders
There is disclosed a method for the treatment or prevention of Extra Pyramidal syndrome (EPS), dystonia, restless legs syndrome (RLS) or periodic leg movement in sleep (PLMS) comprising the administration of an adenosine A2a receptor antagonist, alone or in combination with other agents useful for treating EPS, dystonia, RLS or PLMS; also claimed are pharmaceutical compositions consisting of an adenosine A2a receptor antagonist in combination with an antipsychotic agent, an anticonvulsant agent, lithium or an opioid.
Owner:SCHERING CORP
Device and method for monitoring and assessment of movement disorder symptoms
ActiveUS10085689B1Highly amenable to useImprove portabilityInertial sensorsDiagnostic recording/measuringHuntingtons choreaTreatment choices
The present invention is directed to a device and method for monitoring and assessment of movement disorder symptoms. The device and method disclosed herein are particularly amenable to remote monitoring of a subject's movement disorder symptoms. Briefly stated, in certain preferred embodiments of the present invention the movement disorder monitoring device accompanies a subject to a remote location where the device is used to record data relating to the severity of a subject's movement disorder symptoms over a period of time. This data is then subsequently used by physicians or other clinicians in optimizing and assessing treatment options directed at alleviating a subject's movement disorder symptoms. The method and device of the present invention can be used to monitor symptoms of a number of movement disorders including but not limited to dystonia, essential tremor, Huntington's disease, various ataxias, multiple sclerosis, psychogenic tremor, and Parkinson's disease.
Owner:GREAT LAKES NEUROTECH
Induced Modulation of Neuronal Transmission
The invention is directed to a method of treating movement disorders by the modulation of neuronal transmission using time-variant non-conservative magnetic fields. The invention is also directed to a method for treating dystonias.
Owner:PETTINELLI EUGENE EUSTIS
Methods for treating conditions such as dystonia and post-stroke spasticity with clonidine
ActiveUS8722079B2Good sustained releaseRelieve post-stroke spasticity and/or dystoniaOrganic active ingredientsPill deliveryEffective treatmentPost stroke spasticity
Effective treatments of dystonia and / or post-stroke spasticity for extended periods of time are provided. Through the administration of an effective amount of clonidine at or near a target site, one can relieve dystonia and / or post-stroke spasticity caused by diverse sources. When appropriate formulations are provided within biodegradable polymers, this relief can be continued for at least five days. In some embodiments, the relief can be for at least twenty-five days, at least fifty days, at least one hundred days, at least one hundred and thirty-five days or at least one hundred and eighty days.
Owner:WARSAW ORTHOPEDIC INC
N-aminoalkyldibenzothiopencarboxamide receptor subtype specific ligands
Disclosed are compounds of the formula:or the pharmaceutically acceptable acid addition salts thereof, wherein:R1, R2, R3, R4 are the same or different and represent hydrogen, C1-C6 alkyl, halogen, hydroxy, amino, cyano, nitro, trifluoromethyl, trifluoromethoxy, C1-C6 alkoxy, -O2CR', -NHCOR', -COR', -SOmR', where R' is C1-C6 alkyl and wherein m is 0, 1 or 2; orR1, R2, R3, R4 independently represent -CONR'R'', or -NR'R'' where R' and R'' independently represent hydrogen or C1-C6 alkyl;R5 is hydrogen or C1-C6 alkyl; andR represents an aminoalkyl group,which compounds are useful in the treatment of affective disorders such as schizophrenia, depression, Alzheimer's disease, movement disorders such as Parkinsonism and dystonia, and other disorders which respond to dopaminergic blockade such as substance abuse and obsessive compulsive disorders. Further, compounds of this invention may be useful in treating the extrapyramidal side effects associated with the use of conventional neuroleptic agents.
Owner:NEUROGEN
Methods and Systems for Closed Loop Neurotrophic Delivery Microsystems
Brain Machine Interfaces (BMIs) promise to improve the lives of many patients by providing a direct communication pathway between the brain and one or more external devices. As the brain is an electrochemical system additional signals may improve BMI performance beyond direct electrical signals. Further many psychiatric and neurological disorders such as Parkinson's disease, depression, dystonia, or obsessive compulsive disorder are related to neurotransmitter deficiencies or imbalances. Accordingly detection of neurotransmitter chemicals and / or management of these chemicals may enhance BMIs. Embodiments of the invention provide for implantable CMOS based target derived neurotrophic factor delivery microsystems and neurochemical sensors allowing neurotransmitter deficiencies or imbalances to be detected, monitored, and corrected. Such implantable CMOS solutions provide for high volume, low cost manufacturing as well integration options in arrayed formats as well as integration with other CMOS electronic circuits.
Owner:MUSALLAM WISSAM SAM +1
Urea compounds and their use as enzyme inhibitors
ActiveUS9549915B2Quality improvementHigh yieldOrganic active ingredientsSenses disorderArthritisRisk stroke
A compound having the following structure:or a pharmaceutically acceptable salt or derivative thereof. The compound may be used in the treatment or prevention of a disorder selected from appetite regulation, obesity, metabolic disorders, cachexia, anorexia, pain, inflammation, neurotoxicity, neurotrauma, stroke, multiple sclerosis, spinal cord injury, Parkinson's disease, levodopa-induced dyskinesia, Huntington's disease, Gilles de la Tourette's syndrome, tardive dyskinesia, dystonia, amyotrophic lateral sclerosis, Alzheimer's disease, epilepsy, schizophrenia, anxiety, depression, insomnia, nausea, emesis, alcohol disorders, drug addictions such as opiates, nicotine, cocaine, alcohol and psychostimulants, hypertension, circulatory shock, myocardial reperfusion injury, atherosclerosis, asthma, glaucoma, retinopathy, cancer, inflammatory bowel disease, acute and chronic liver disease such as hepatitis and liver cirrhosis, arthritis and osteoporosis.
Owner:BIAL PORTELA & CA SA
Adenosine A2a receptor antagonists for the treatment of extra-pyramidal syndrome and other movement disorders
There is disclosed a method for the treatment or prevention of Extra Pyramidal syndrome (EPS), dystonia, restless legs syndrome (RLS) or periodic leg movement in sleep (PLMS) comprising the administration of an adenosine A2a receptor antagonist, alone or in combination with other agents useful for treating EPS, dystonia, RLS or PLMS.
Owner:SCHERING CORP
Animal model with disrupted Fgf14 gene
InactiveUS20030037354A1Effective trafficMicrobiological testing/measurementNucleic acid vectorExonNeuropharmacology
The disclosure describes a unique animal model which is useful for studying the role of FGF14 in the central nervous system (CNS) and testing of potential drugs for treatment of CNS diseases. To provide this animal model, the Fgf14 gene is disrupted in mice by replacing the second and third exons with beta-galactosidase. Neuropharmacological studies are disclosed which show that the Fgf14 deficient mice have disrupted striatal-nigra and striatal-pallidal pathways resulting in increased excitatory input to the cortex. The paroxysmal hyperkinetic disorder in Fgf14 deficient mice phenocopies a form of dystonia, a disease often associated with dysfunction of the putamen.
Owner:WASHINGTON UNIV IN SAINT LOUIS
Treatment of Tremor with Histamine H3 Inverse Agonists or Hist Amine H3 Antagonists
Histamine H3 inverse agonists or histamine H3 antagonists are useful, alone or in combination with a neuroleptic agent, for treating or preventing movement disorders, including tremor, such as essential tremor, and tremor associated with Parkinson's disease, cranofacial trauma, multiple sclerosis, stroke, dystonia, and neuropathic, toxic or drug induced tremor.
Owner:MERCK SHARP & DOHME CORP
Potassium Channel Activators for the Prevention and Treatment of Dystonia and Dystonia-Like Symptoms
InactiveUS20090137641A1Suppress symptomsInhibitory activityBiocideNervous disorderPotassium channel openerPotassium
The present invention is directed to the prevention, reversal and medical treatment of dystonia and dyskinesia as well as other diseases related to movement disorders, both in human beings and animals by administering a neuronal potassium channel opener such as flupirtine, retigabine or maxipost.
Owner:RUNDFELDT CHRIS +1
Potassium Channel Activators for the Prevention and Treatment of Dystonia and Dystonia Like Symptoms
InactiveUS20090318507A2Suppress symptomsInhibitory activityBiocideNervous disorderPotassium channel openerPotassium
Owner:RUNDFELDT CHRIS +1
Movement disorder therapy system, devices and methods, and methods of remotely tuning
ActiveUS11040198B1Expand accessShorten the timeMedical simulationHead electrodesHuntingtons choreaEmergency medicine
The present invention relates to methods for remotely tuning treatment parameters in movement disorder therapy systems where the subject and clinician are located remotely from each other. The present invention still further provides methods of quantifying movement disorders for the treatment of patients who exhibit symptoms of such movement disorders including, but not limited to, Parkinson's disease and Parkinsonism, Dystonia, Chorea, and Huntington's disease, Ataxia, Tremor and Essential Tremor, Tourette syndrome, stroke, and the like. The present invention yet further relates to methods of remotely tuning a therapy device using objective quantified movement disorder symptom data to determine the therapy setting or parameters to be transmitted and provided to the subject via his or her therapy device. The present invention also provides treatment and tuning remotely, allowing for home monitoring of subjects.
Owner:GREAT LAKES NEUROTECHNOLOGIES INC
DRD (Dope-Reactive Dystonia)-related gene mutation and detecting method and usage thereof
ActiveCN103725687AMicrobiological testing/measurementFermentationDopa-Responsive DystoniaTyrosine hydroxylase
The invention belongs to the field of molecular pathology and particularly relates to a DRD (Dope-Reactive Dystonia)-related gene mutation, in particular to two mutant types of a DRD-related TH (Tyrosine hydroxylase) gene.
Owner:XIANGYA HOSPITAL CENT SOUTH UNIV +1
Movement disorder therapy system, devices and methods, and methods of remotely tuning
ActiveUS11040203B1Expand accessShorten the timeMedical simulationHead electrodesHuntingtons choreaEmergency medicine
The present invention relates to methods for remotely tuning treatment parameters in movement disorder therapy systems where the subject and clinician are located remotely from each other. The present invention still further provides methods of quantifying movement disorders for the treatment of patients who exhibit symptoms of such movement disorders including, but not limited to, Parkinson's disease and Parkinsonism, Dystonia, Chorea, and Huntington's disease, Ataxia, Tremor and Essential Tremor, Tourette syndrome, stroke, and the like. The present invention yet further relates to methods of remotely tuning a therapy device using objective quantified movement disorder symptom data to determine the therapy setting or parameters to be transmitted and provided to the subject via his or her therapy device. The present invention also provides treatment and tuning remotely, allowing for home monitoring of subjects.
Owner:GREAT LAKES NEUROTECHNOLOGIES INC
Urea compounds and their use as enzyme inhibitors
ActiveUS20170101381A1Quality improvementHigh yieldOrganic active ingredientsSenses disorderNausea sicknessArthritis
Owner:BIAL PORTELA & CA SA
Method of treating or preventing central nervous system disorders with compounds having selectivity for the alpha 3 subunit of the benzodiazepine receptor
Owner:BOEHRINGER LNGELHEIM VETMEDICA GMBH
Palatable compositions including sodium phenylbutyrate and uses thereof
InactiveUS20170266115A1Quantity minimizationHigh drug loadingOrganic active ingredientsNervous disorderSpinal muscular atrophiesInborn error of metabolism
The present invention features palatable pharmaceutical compositions including sodium phenylbutyrate and methods for the treatment of inborn errors of metabolism (e.g., Maple Syrup Urine Disease or Urea Cycle Disorders), neurodegenerative disorders such as Parkinson's disease, spinal muscular atrophy, dystonia, or inclusion-body myositis with such compositions.
Owner:ACER THERAPEUTICS INC
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Patsnap Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com